Efficacies of quinupristin-dalfopristin combined with vancomycin in vitro and in experimental endocarditis due to methicillin-resistant Staphylococcus aureus in relation to cross-resistance to macrolides, lincosamides, and streptogramin B- type antibiotics.
A beneficial effect of the combination of quinupristin-dalfopristin and vancomycin was observed against two methicillin-resistant strains of Staphylococcus aureus harboring or not harboring the ermC gene, which codes for constitutive macrolide, lincosamide, and streptogramin B resistance. The beneficial effect was observed in time-kill studies, in which the drugs were used at inhibitory concentrations, and in a rabbit model of endocarditis, in which the combination was highly bactericidal and more active than monotherapies.
Pavie
Juliette
J
Institut National de la Santé et de la Recherche Médicale (EMI 9933), Faculté de Médecine Xavier Bichat, Paris.
Lefort
Agnès
A
Zarrouk
Virginie
V
Chau
Françoise
F
Garry
Louis
L
Leclercq
Roland
R
Fantin
Bruno
B
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D003470:Culture Media; D004351:Drug Resistance; D004359:Drug Therapy, Combination / Q000494:pharmacology* / Q000627:therapeutic use*; D004697:Endocarditis, Bacterial / Q000188:drug therapy* / Q000382:microbiology; D055231:Lincosamides; D018942:Macrolides; D016106:Methicillin Resistance; D008826:Microbial Sensitivity Tests; D011817:Rabbits; D013211:Staphylococcus aureus / Q000187:drug effects*; D025381:Streptogramin B / Q000494:pharmacology; D013997:Time Factors; D014640:Vancomycin / Q000494:pharmacology* / Q000627:therapeutic use*; D014769:Virginiamycin / Q000494:pharmacology* / Q000627:therapeutic use*
D000900:Anti-Bacterial Agents; D003470:Culture Media; D055231:Lincosamides; D018942:Macrolides; D014769:Virginiamycin; C062940:quinupristin-dalfopristin; D025381:Streptogramin B; D014640:Vancomycin